Non-erosive Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is prevalent globally and represents one of the most common gastrointestinal diseases.  The term GERD covers a spectrum of conditions including non-erosive gastroesophageal reflux disease. (NERD) This condition is defined as at least weekly heartburn and/or regurgitation.  Vonprazan is in a new class of acid-inhibitory agents called potassium competitive blockers.  Recent studies have shown a rapid onset of action after the first dose providing relief.

What we need:
  • The subject is ≥18 years of age at the time of informed consent signing
  • The subject identified their main symptom as heartburn, a burning sensation in the retrosternal area (behind the breastbone)
  • History of episodes of heartburn for 6 months or longer prior to screening
  • Heartburn reported on 4 or more days during any 7 consecutive days in the Screening Period as recorded in the electronic diary
  • What we cannot have:
  • The subject has irritable bowel syndrome (IBS)
  • The subject has endoscopic Barrett’s esophagus (>1 cm of columnar-lined esophagus) and/or definite dysplastic changes in the esophagus
  • The subject has a history of surgery or endoscopic treatment affecting gastroesophageal reflux, including fundoplication and dilation for esophageal stricture (except Schatzki’s ring) or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps)
  • The subject has any other condition affecting the esophagus (Ask to view the full list of conditions)
  • Get the latest news and updates from Investigative Clinical Research